scholarly journals Vaccines in control of infectious diseases of swine

2021 ◽  
Vol 77 (04) ◽  
pp. 176-182
Author(s):  
KAZIMIERZ TARASIUK
Keyword(s):  
Infectious Diseases ◽  
Influenza A Virus ◽  
Neutralizing Antibodies ◽  
Influenza A ◽  
Classical Swine Fever ◽  
Genetic Changes ◽  
Live Vaccines ◽  
Intradermal Administration ◽  
Inactivated Vaccines ◽  
And Control

The study presents data concerning vaccines registered in the EU that are used in the prevention and control of viral and bacterial infectious diseases of swine in Poland. It discusses novel vaccines against infectious diseases of swine, such as ileitis, influenza A virus, and mycoplasmal pneumonia. The advantages of intradermal administration of selected vaccines against certain diseases are discussed. Selected problems regarding the efficacy of vaccination against influenza A virus and PRRS are underlined. The study points out that the efficacy of immunization with inactivated vaccines against PRRS is limited. This, however, may also be true of live vaccines against PRRS, since results of immunization with some live attenuated vaccines can be unsatisfactory as well. It is explained by the fact that there are relatively frequent genetic changes in the genome of the field PRRSV strains, unlike in the virus strain or strains used in the vaccine. Strategies to optimize the use of currently available vaccines against influenza A virus (IAV) are discussed. It is worth noting the high efficacy of the vaccine containing antigens of subtypes H1N1, H3N2, and H1N1 against influenza A virus. Vaccination against IAV induces the production of neutralizing antibodies and protection with a very similar strain. As far as vaccines against viral diseases of swine (pseudorabies, classical swine fever) are concerned, the marker vaccines appear to be very useful in differentiating infected animals from vaccinated ones (DIVA strategy). At the beginning of the 21st century, several new effective vaccines were developed, produced, and used against diarrheal diseases of different etiology and, for the first time, against oedema disease, ileitis, and enzootic pneumonia of swine. In view of the growing problem of mixed infections, the study presents several new vaccines containing multiple antigens of one pathogen (serotypes/genotypes) or different pathogens in combination (polyvalent vaccines). The study also discusses the role of the strategy of vaccination depending on the course of the infectious disease, the type of vaccine, as well as the production system of swine.

scholarly journals Progress in the development of vaccines and strategies of their application in the control of infectious diseases of swine

2020 ◽  
Vol 76 (03) ◽  
pp. 6384-2020
Author(s):  
ZYGMUNT PEJSAK ◽  
MARIAN TRUSZCZYŃSKI ◽  
HANNA LUTNICKA
Keyword(s):  
Infectious Diseases ◽  
Recombinant Vaccine ◽  
Genetic Changes ◽  
Live Vaccines ◽  
E Coli ◽  
Inactivated Vaccines ◽  
Baculovirus System ◽  
And Control ◽  
First Time ◽  
Oedema Disease

Data are presented concerning vaccines used in the prophylaxis and control of some viral and bacterial infectious diseases of swine, particularly against: MPS, PRRS, PMWS CSF, AD, SI, E. coli, Cl. perfringens type C and A and oedema disease. The lower efficacy in immunization of inactivated vaccines is stressed. However in case of live vaccines against PRRS this is not always the case since also live attenuated vaccines deliver unsatisfactory results of immunization. This is explained by frequently occurring genetic changes in the genome of the field PRRSV strains in comparison with the strain or strains being in the vaccine. Vaccines against PMWS are characterized, underlining high efficacy of the vaccines in the Baculovirus system. After withdrawing from field use against CSF the vaccines Lapest and Cellpest a recombinant vaccine against CSF was introduced for control of this disease. A recombinant vaccine against AD of swine is mentioned, which was successfully used in eradication program in Europe. Of high practical value is mentioned a vaccine against SI containing subptypes H1N1, H3N2 and H1N1. Referring to vaccines against viral diseases of swine marker vaccines were mentioned enabling differentiation of animals infected from vaccinated (DIVA strategy). At the beginning of the XXI century several new and effective vaccines were developed, produced and used against diarrheal diseases of different etiology and for the first time against oedema disease. The role of strategy of vaccination depending on the characteristic of the infectious disease, the vaccine and the production system of swine is present.

scholarly journals Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus

2016 ◽  
Vol 113 (42) ◽  
pp. 11931-11936 ◽  
Author(s):  
Wenqian He ◽  
Gene S. Tan ◽  
Caitlin E. Mullarkey ◽  
Amanda J. Lee ◽  
Mannie Man Wai Lam ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Influenza A Virus ◽  
Neutralizing Antibodies ◽  
Influenza A ◽  
Critical Role ◽  
Host Cells ◽  
Viral Glycoprotein ◽  
Effector Functions ◽  
Dependent Cell

The generation of strain-specific neutralizing antibodies against influenza A virus is known to confer potent protection against homologous infections. The majority of these antibodies bind to the hemagglutinin (HA) head domain and function by blocking the receptor binding site, preventing infection of host cells. Recently, elicitation of broadly neutralizing antibodies which target the conserved HA stalk domain has become a promising “universal” influenza virus vaccine strategy. The ability of these antibodies to elicit Fc-dependent effector functions has emerged as an important mechanism through which protection is achieved in vivo. However, the way in which Fc-dependent effector functions are regulated by polyclonal influenza virus-binding antibody mixtures in vivo has never been defined. Here, we demonstrate that interactions among viral glycoprotein-binding antibodies of varying specificities regulate the magnitude of antibody-dependent cell-mediated cytotoxicity induction. We show that the mechanism responsible for this phenotype relies upon competition for binding to HA on the surface of infected cells and virus particles. Nonneutralizing antibodies were poor inducers and did not inhibit antibody-dependent cell-mediated cytotoxicity. Interestingly, anti-neuraminidase antibodies weakly induced antibody-dependent cell-mediated cytotoxicity and enhanced induction in the presence of HA stalk-binding antibodies in an additive manner. Our data demonstrate that antibody specificity plays an important role in the regulation of ADCC, and that cross-talk among antibodies of varying specificities determines the magnitude of Fc receptor-mediated effector functions.

scholarly journals Evaluation of Live Attenuated Influenza A Virus H6 Vaccines in Mice and Ferrets

2008 ◽  
Vol 83 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Zhongying Chen ◽  
Celia Santos ◽  
Amy Aspelund ◽  
Laura Gillim-Ross ◽  
Hong Jin ◽  
...  
Keyword(s):  
Influenza A Virus ◽  
Neutralizing Antibodies ◽  
Influenza A ◽  
Serum Antibody ◽  
Cross Reactivity ◽  
Phenotypic Properties ◽  
Vaccine Candidates ◽  
Virus Challenge ◽  
Avian Influenza A Virus ◽  
Internal Gene

ABSTRACT Avian influenza A virus A/teal/HK/W312/97 (H6N1) possesses seven gene segments that are highly homologous to those of highly pathogenic human influenza H5N1 viruses, suggesting that a W312-like H6N1 virus might have been involved in the generation of the A/HK/97 H5N1 viruses. The continuous circulation and reassortment of influenza H6 subtype viruses in birds highlight the need to develop an H6 vaccine to prevent potential influenza pandemics caused by the H6 viruses. Based on the serum antibody cross-reactivity data obtained from 14 different H6 viruses from Eurasian and North American lineages, A/duck/HK/182/77, A/teal/HK/W312/97, and A/mallard/Alberta/89/85 were selected to produce live attenuated H6 candidate vaccines. Each of the H6 vaccine strains is a 6:2 reassortant ca virus containing HA and NA gene segments from an H6 virus and the six internal gene segments from cold-adapted A/Ann Arbor/6/60 (AA ca), the master donor virus that is used to make live attenuated influenza virus FluMist (intranasal) vaccine. All three H6 vaccine candidates exhibited phenotypic properties of temperature sensitivity (ts), ca, and attenuation (att) conferred by the internal gene segments from AA ca. Intranasal administration of a single dose of the three H6 ca vaccine viruses induced neutralizing antibodies in mice and ferrets and fully protected mice and ferrets from homologous wild-type (wt) virus challenge. Among the three H6 vaccine candidates, the A/teal/HK/W312/97 ca virus provided the broadest cross-protection against challenge with three antigenically distinct H6 wt viruses. These data support the rationale for further evaluating the A/teal/HK/W312/97 ca vaccine in humans.

scholarly journals Memory regulatory T cells home to the lung and control influenza A virus infection

2019 ◽  
Vol 97 (9) ◽  
pp. 774-786 ◽  
Author(s):  
Chunni Lu ◽  
Damien Zanker ◽  
Peter Lock ◽  
Xiangrui Jiang ◽  
Jieru Deng ◽  
...  
Keyword(s):  
T Cells ◽  
Virus Infection ◽  
Regulatory T Cells ◽  
Influenza A Virus ◽  
Influenza A ◽  
Influenza A Virus Infection ◽  
And Control

scholarly journals Age at Vaccination and Timing of Infection Do Not Alter Vaccine-Associated Enhanced Respiratory Disease in Influenza A Virus-Infected Pigs

2016 ◽  
Vol 23 (6) ◽  
pp. 470-482 ◽  
Author(s):  
Carine K. Souza ◽  
Daniela S. Rajão ◽  
Crystal L. Loving ◽  
Phillip C. Gauger ◽  
Daniel R. Pérez ◽  
...  
Keyword(s):  
Respiratory Disease ◽  
Influenza A Virus ◽  
Influenza A ◽  
Control Groups ◽  
Swine Industry ◽  
Vaccine Component ◽  
Live Attenuated Influenza Virus ◽  
And Control ◽  
The Impact

ABSTRACTWhole inactivated virus (WIV) vaccines are widely used in the swine industry to reduce clinical disease against homologous influenza A virus (IAV) infection. In pigs experimentally challenged with antigenically distinct heterologous IAV of the same hemagglutinin subtype, WIV vaccinates have been shown to develop vaccine-associated enhanced respiratory disease (VAERD). We evaluated the impact of vaccine valency, age at vaccination, and duration between vaccination and challenge on the development of VAERD using vaccine containing δ1-H1N2 and challenge with pandemic H1N1 (pH1N1) virus. Pigs were vaccinated with monovalent WIV MN08 (δ1-H1N2) and bivalent (δ1-H1N2–H3N2 or δ1-H1N2–pH1N1) vaccines and then were challenged with pH1N1 at 3 weeks postboost (wpb). Another group was vaccinated with the same monovalent WIV and challenged at 6 wpb to determine if the time postvaccination plays a role in the development of VAERD. In a follow-up study, the impact of age of first WIV vaccination (at 4 versus 9 weeks of age) with a boost 3 weeks later (at 7 versus 12 weeks of age) was evaluated. A monovalent live-attenuated influenza virus (LAIV) vaccine administered at 4 and 7 weeks of age was also included. All mismatched WIV groups had significantly higher lung lesions than the LAIV, bivalent MN08-CA09, and control groups. Age of first vaccination or length of time between booster dose and subsequent challenge did not alter the development of VAERD in WIV-vaccinated pigs. Importantly, the mismatched component of the bivalent MN08-CA09 WIV did not override the protective effect of the matched vaccine component.

scholarly journals Influenza A virus superinfection potential is regulated by viral genomic heterogeneity

2018 ◽  
Author(s):  
Jiayi Sun ◽  
Christopher B. Brooke
Keyword(s):  
Influenza A Virus ◽  
Influenza A ◽  
Control Strategies ◽  
Natural Infection ◽  
Viral Gene ◽  
Evolutionary Potential ◽  
Viral Genes ◽  
Prediction And Control ◽  
Complete Set ◽  
And Control

AbstractDefining the specific factors that govern the evolution and transmission of influenza A virus (IAV) populations is of critical importance for designing more effective prediction and control strategies. Superinfection, the sequential infection of a single cell by two or more virions, plays an important role in determining the replicative and evolutionary potential of IAV populations. The prevalence of superinfection during natural infection, and the specific mechanisms that regulate it, remain poorly understood. Here, we used a novel single virion infection approach to directly assess the effects of individual IAV genes on superinfection efficiency. Rather than implicating a specific viral gene, this approach revealed that superinfection susceptibility is determined by the total number of viral genes expressed, independent of their identity. IAV particles that expressed a complete set of viral genes potently inhibit superinfection, while semi-infectious particles (SIPs) that express incomplete subsets of viral genes do not. As a result, virus populations that contain more SIPs undergo more frequent superinfection. These findings identify both a major determinant of IAV superinfection potential and a prominent role for SIPs in promoting viral co-infection.

scholarly journals Analysis of the Genetic Diversity Associated With the Drug Resistance and Pathogenicity of Influenza A Virus Isolated in Bangladesh From 2002 to 2019

2021 ◽  
Vol 12 ◽  
Author(s):  
Md. Golzar Hossain ◽  
Sharmin Akter ◽  
Priya Dhole ◽  
Sukumar Saha ◽  
Taheruzzaman Kazi ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Drug Resistance ◽  
Influenza A Virus ◽  
Influenza A ◽  
Neuraminidase Inhibitor ◽  
Avian Species ◽  
Lower Prevalence ◽  
Bioinformatic Tools ◽  
Wide Range ◽  
And Control

The subtype prevalence, drug resistance- and pathogenicity-associated mutations, and the distribution of the influenza A virus (IAV) isolates identified in Bangladesh from 2002 to 2019 were analyzed using bioinformatic tools. A total of 30 IAV subtypes have been identified in humans (4), avian species (29), and environment (5) in Bangladesh. The predominant subtypes in human and avian species are H1N1/H3N2 and H5N1/H9N2, respectively. However, the subtypes H5N1/H9N2 infecting humans and H3N2/H1N1 infecting avian species have also been identified. Among the avian species, the maximum number of subtypes (27) have been identified in ducks. A 3.56% of the isolates showed neuraminidase inhibitor (NAI) resistance with a prevalence of 8.50, 1.33, and 2.67% in avian species, humans, and the environment, respectively, the following mutations were detected: V116A, I117V, D198N, I223R, S247N, H275Y, and N295S. Prevalence of adamantane-resistant IAVs was 100, 50, and 30.54% in humans, the environment, and avian species, respectively, the subtypes H3N2, H1N1, H9N2, and H5N2 were highly prevalent, with the subtype H5N1 showing a comparatively lower prevalence. Important PB2 mutations such D9N, K526R, A588V, A588I, G590S, Q591R, E627K, K702R, and S714R were identified. A wide range of IAV subtypes have been identified in Bangladesh with a diversified genetic variation in the NA, M2, and PB2 proteins providing drug resistance and enhanced pathogenicity. This study provides a detailed analysis of the subtypes, and the host range of the IAV isolates and the genetic variations related to their proteins, which may aid in the prevention, treatment, and control of IAV infections in Bangladesh, and would serve as a basis for future investigations.

scholarly journals Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages

mBio ◽  
2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Kizzmekia S. Corbett ◽  
Syed M. Moin ◽  
Hadi M. Yassine ◽  
Alberto Cagigi ◽  
Masaru Kanekiyo ◽  
...  
Keyword(s):  
Influenza Virus ◽  
B Cells ◽  
Influenza A Virus ◽  
Neutralizing Antibodies ◽  
Influenza A ◽  
Common Ancestor ◽  
Influenza Vaccines ◽  
Broadly Neutralizing Antibodies ◽  
Self Assembling ◽  
Group 2

ABSTRACTInfluenza vaccines targeting the highly conserved stem of the hemagglutinin (HA) surface glycoprotein have the potential to protect against pandemic and drifted seasonal influenza viruses not covered by current vaccines. While HA stem-based immunogens derived from group 1 influenza A viruses have been shown to induce intragroup heterosubtypic protection, HA stem-specific antibody lineages originating from group 2 may be more likely to possess broad cross-group reactivity. We report the structure-guided development of mammalian-cell-expressed candidate vaccine immunogens based on influenza A virus group 2 H3 and H7 HA stem trimers displayed on self-assembling ferritin nanoparticles using an iterative, multipronged approach involving helix stabilization, loop optimization, disulfide bond addition, and side-chain repacking. These immunogens were thermostable, formed uniform and symmetric nanoparticles, were recognized by cross-group-reactive broadly neutralizing antibodies (bNAbs) with nanomolar affinity, and elicited protective, homosubtypic antibodies in mice. Importantly, several immunogens were able to activate B cells expressing inferred unmutated common ancestor (UCA) versions of cross-group-reactive human bNAbs from two multidonor classes, suggesting they could initiate elicitation of these bNAbs in humans.IMPORTANCECurrent influenza vaccines are primarily strain specific, requiring annual updates, and offer minimal protection against drifted seasonal or pandemic strains. The highly conserved stem region of hemagglutinin (HA) of group 2 influenza A virus subtypes is a promising target for vaccine elicitation of broad cross-group protection against divergent strains. We used structure-guided protein engineering employing multiple protein stabilization methods simultaneously to develop group 2 HA stem-based candidate influenza A virus immunogens displayed as trimers on self-assembling nanoparticles. Characterization of antigenicity, thermostability, and particle formation confirmed structural integrity. Group 2 HA stem antigen designs were identified that, when displayed on ferritin nanoparticles, activated B cells expressing inferred unmutated common ancestor (UCA) versions of human antibody lineages associated with cross-group-reactive, broadly neutralizing antibodies (bNAbs). Immunization of mice led to protection against a lethal homosubtypic influenza virus challenge. These candidate vaccines are now being manufactured for clinical evaluation.

Sign in / Sign up

Export Citation Format

Share Document